Sotera Health Company
SHC
17.90
-0.35
-1.92%
Sotera Health Company
US · SHC
#2097 by market cap
Listed 2020
17.90
-0.35
-1.92%
Live - 5344 symbols - heartbeat 217s ago
· 2026-10-08 07:56
Pre-market
18.08
+0.98%
After-hours
17.90
0.00%
- Market cap
- 5.11B
- P/E (TTM)i
- 31.40
- P/Bi
- 7.67
- EPSi
- 0.27
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on SHC?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.78, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +5.74% YoY
Margins
- Gross margin
- 55.48%
- Operating margin
- 31.11%
- Net margin
- 6.70%
Key ratios & quality
- Enterprise valuei
- 6.91B
- Altman Z-Scorei
- 1.78
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 746.15M | 778.33M | 818.16M | 931.48M | 1.00B | 1.05B | 1.10B | 1.16B |
| Gross profit | 357.25M | 395.43M | 443.57M | 518.67M | 557.00M | 577.16M | 602.30M | 645.53M |
| Selling & admin expenses | 133.36M | 147.48M | 178.53M | 198.16M | 245.71M | 236.67M | 242.63M | 252.76M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 165.91M | 189.39M | 206.02M | 256.73M | 248.35M | 276.69M | 297.63M | 362.03M |
| Pretax profit | 24.22M | -916.00K | -38.86M | 175.72M | -243.11M | 106.03M | 113.87M | 147.51M |
| Tax | 30.10M | 19.51M | -1.37M | 58.60M | -9.54M | 54.65M | 69.48M | 69.56M |
| Net profit | -5.88M | -20.43M | -37.49M | 117.12M | -233.57M | 51.38M | 44.40M | 77.95M |
| Basic EPS | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 |
| Diluted EPS | -0.02 | -0.08 | -0.16 | 0.41 | -0.83 | 0.18 | 0.16 | 0.27 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 254.52M | 294.34M | 311.31M | 303.44M | 280.05M | 321.38M |
| Gross profit | 135.43M | 166.62M | 177.56M | 165.92M | 147.07M | 177.96M |
| Selling & admin expenses | 63.06M | 68.89M | 63.29M | 57.51M | 68.21M | 68.16M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 57.04M | 88.43M | 111.18M | 105.38M | 75.83M | 106.79M |
| Pretax profit | -14.82M | 18.90M | 72.94M | 70.50M | 42.61M | 78.05M |
| Tax | -1.56M | 10.94M | 24.54M | 35.65M | 16.02M | 24.41M |
| Net profit | -13.26M | 7.96M | 48.40M | 34.85M | 26.59M | 53.64M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.05 | 0.03 | 0.17 | 0.12 | 0.09 | 0.19 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 312.86M | 252.35M | 315.02M | 345.96M | 645.01M | 557.24M | 526.04M | 613.41M |
| Cash & ST investments | 96.27M | 62.86M | 102.45M | 106.92M | 395.21M | 296.41M | 277.24M | 344.62M |
| Inventory | 37.60M | 37.40M | 34.09M | 54.29M | 37.15M | 48.32M | 49.16M | 54.38M |
| Total assets | 2.71B | 2.58B | 2.76B | 2.79B | 3.12B | 3.13B | 3.07B | 3.26B |
| Total current liabilities | 143.37M | 123.99M | 140.60M | 161.16M | 791.57M | 230.65M | 191.00M | 249.58M |
| Short-term debt | 16.70M | 17.62M | 10.56M | 10.45M | 206.40M | 19.50M | 22.78M | 23.19M |
| Long-term debt | 2.19B | 2.80B | 1.82B | 1.74B | 1.75B | 2.22B | 2.21B | 2.13B |
| Total liabilities | 2,663,093,000.00 | 3,221,806,000.00 | 2,306,705,000.00 | 2,203,406,000.00 | 2,767,467,000.00 | 2,686,686,000.00 | 2,666,737,000.00 | 2,657,155,000.00 |
| Total equity | 45.49M | -641.13M | 454.57M | 586.10M | 350.24M | 443.73M | 404.91M | 606.04M |
| Retained earnings | -10.42M | -550.51M | -589.13M | -472.25M | -705.82M | -654.44M | -610.04M | -532.09M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 554.99M | 608.18M | 577.82M | 613.41M | 585.97M | 646.46M |
| Cash & ST investments | 304.39M | 332.44M | 299.19M | 344.62M | 314.15M | 356.72M |
| Inventory | 61.05M | 59.95M | 49.87M | 54.38M | 57.49M | 56.37M |
| Total assets | 3.10B | 3.22B | 3.19B | 3.26B | 3.24B | 3.31B |
| Total current liabilities | 225.99M | 246.32M | 242.40M | 249.58M | 207.80M | 231.24M |
| Short-term debt | 22.93M | 23.66M | 22.90M | 23.19M | 23.35M | 23.13M |
| Long-term debt | 2.21B | 2.20B | 2.13B | 2.13B | 2.12B | 2.13B |
| Total liabilities | 2,683,437,000.00 | 2,705,446,000.00 | 2,635,691,000.00 | 2,657,155,000.00 | 2,613,393,000.00 | 2,641,142,000.00 |
| Total equity | 414.09M | 511.28M | 550.47M | 606.04M | 622.51M | 665.65M |
| Retained earnings | -623.30M | -615.34M | -566.94M | -532.09M | -505.50M | -451.86M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 119.56M | 149.04M | 120.59M | 281.55M | 277.96M | -147.73M | 224.16M | 287.20M |
| Depreciation & amortization | 146.82M | 146.72M | 143.56M | 150.90M | 145.55M | 157.93M | 163.64M | 136.71M |
| Free cash flow | 46.95M | 91.78M | 67.08M | 179.38M | 95.58M | -362.71M | 45.09M | 149.18M |
| Dividends paid | -175.85M | -691.17M | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 1.12B | -- | -- | -- | -- | -- |
| Ending cash balance | 96.79M | 63.03M | 102.45M | 106.92M | 396.29M | 301.65M | 278.87M | 346.46M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 55.52M | 57.42M | 71.15M | 103.10M | 29.44M | 88.50M |
| Depreciation & amortization | 40.80M | 35.02M | 28.36M | 32.53M | 30.81M | 33.40M |
| Free cash flow | 35.60M | 26.19M | 34.98M | 52.41M | -16.73M | 42.05M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 306.08M | 334.27M | 301.03M | 346.46M | 315.95M | 356.73M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -13.23 | -- | -- | 22.51 | -49.89 | 12.94 | 10.46 | 15.42 |
| ROA %i | -0.22 | -0.79 | -1.45 | 4.21 | -7.91 | 1.64 | 1.43 | 2.46 |
| ROIC %i | 4.33 | -- | -- | 6.97 | -6.53 | 6.37 | 6.32 | 7.13 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- | 2.29 |
| EBIT margin %i | 22.46 | 20.15 | 21.56 | 26.83 | -16.24 | 23.72 | 25.31 | 26.06 |
| FCF / sales %i | 6.29 | 11.79 | 8.20 | 19.26 | 9.52 | -- | 4.10 | 12.82 |
| Current ratioi | 2.18 | 2.04 | 2.24 | 2.15 | 0.81 | 2.42 | 2.75 | 2.46 |
| Quick ratioi | 1.66 | 1.41 | 1.66 | 1.50 | 0.70 | 2.05 | 2.32 | 2.09 |
| Debt / assetsi | 82.62 | 110.37 | 69.14 | 65.53 | 65.18 | 74.34 | 76.53 | 69.68 |
| LT debt / equityi | 5,007.10 | -- | 419.78 | 310.09 | 521.26 | 520.03 | 574.90 | 371.34 |
| Interest coveragei | 1.17 | 0.99 | 0.82 | 3.37 | -2.03 | 1.74 | 1.69 | 1.95 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 7.68 | 8.85 | 8.65 | 5.71 | 5.05 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -27.58 | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | 56.33 | 1.36 | -- | -36.89 | 16.00 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 5.89 | 5.15 | 10.87 | 15.42 | 22.73 | 27.78 |
| ROA %i | 0.81 | 0.77 | 1.75 | 2.46 | 3.72 | 5.01 |
| ROIC %i | 5.57 | 5.46 | 6.48 | 7.13 | 7.34 | 8.70 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 22.75 | 22.75 | 24.65 | 26.06 | 29.81 | 33.50 |
| FCF / sales %i | 9.57 | 10.02 | 7.53 | 12.82 | 8.14 | 9.27 |
| Current ratioi | 2.46 | 2.47 | 2.38 | 2.46 | 2.82 | 2.80 |
| Quick ratioi | 2.02 | 2.08 | 2.04 | 2.09 | 2.36 | 2.40 |
| Debt / assetsi | 75.75 | 73.05 | 71.48 | 69.68 | 70.16 | 68.59 |
| LT debt / equityi | 561.12 | 454.95 | 409.55 | 371.34 | 360.95 | 337.26 |
| Interest coveragei | 1.54 | 1.56 | 1.75 | 1.95 | 2.37 | 2.84 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Sterigenics is the largest reported line at 65.83% of revenue, across 3 reported segments.
- Nelson Labs follows at 18.87%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Sterigenics65.83%
Nelson Labs18.87%
Nordion15.29%
Quote time 2026-10-08 07:56:41 · For reference only, not investment advice and not tailored to your situation.